Empagliflozin in Patients With Cirrhosis and Ascites (NCT05726032)

🧪 Interventions in This Study

• Empagliflozin 10 MG (DRUG)
• Matching Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Yale University — New Haven, Connecticut

📞 Contact the Study Coordinator

Phone: (203) 737-3571

Email: veena.s.rao@yale.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Cirrhosis

• Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement — Richmond, Virginia
• Liver Cirrhosis Network Cohort Study — La Jolla, California
• Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis — Los Angeles, California
• Oral Health In Cirrhosis of the Liver (ORACLE) — Richmond, Virginia
• Remote Electrical Stimulation for Pain and Depression Treatment in Cirrhosis — Ann Arbor, Michigan
• Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis — San Francisco, California

Explore by condition: All Cirrhosis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.